Clinical trialPhase 2Terminated
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
A Phase II Trial of Mutation-Targeted Therapy With Sunitinib or Everolimus in Patients With Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
- Outcome
- Stopped early. Results posted; no analysis attachedStudy closed due to poor accrual. (Enrollment)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 8 April 2015
- Ended
- 22 May 2019
- Enrollment
- 16 participants
- Sites
- 1
- Primary outcomes
- Median Amount of Time Subject Survives Without Disease Progression After Treatment
- Sponsor type
- NIH
- Results posted
- 9 September 2020
- Last update
- 9 September 2020
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 9 September 2020
- Primary outcome
- Median Amount of Time Subject Survives Without Disease Progression After TreatmentSunitinib First, Everolimus Second: 7 (3 to 15), n = 14Everolimus First, Sunitinib Second: 18 (0 to 18), n = 2Values: median months, Full RangeTime frame: Up to approximately 2 yearsNo analysis posted for this outcome (outcome 1)
- Participants
- Sunitinib Followed by Everolimus: 14 started, 9 completedEverolimus Followed by Sunitinib: 2 started, 1 completed
- Serious adverse events
- Sunitinib: 3 of 15Everolimus: 2 of 11Participants with at least one serious adverse event, of those at risk, as posted
- Reported in
- ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCR… DOI 10.4158/ep-2018-0603↗ Linked as this trial’s results paper. The numbers above are the registry’s, not the paper’s.
4 secondary outcomes
- ORR · Number of Participants With an Overall Response
- Sunitinib First, Everolimus Second 1/14; Everolimus First, Sunitinib Second 0/2 [Participants]
- OS · Overall Survival
- Sunitinib First, Everolimus Second 25.5 (6 to 39), n=14; Everolimus First, Sunitinib Second 10.7 (0.427397 to 21), n=2 [median Months, Full Range]
- Median Survival Time (MST)
- Sunitinib First, Everolimus Second 9.5 (0.4927 to 33), n=14; Everolimus First, Sunitinib Second 5.5 (0 to 11), n=2 [median Months, Full Range]
- Number of Participants With Serious and Non-Serious Adverse Events
- Sunitinib 15/15; Everolimus 11/11 [Participants]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Background: \- Neuroendocrine tumors (NETs) come from cells of the hormonal and nervous systems. Some people have surgery to shrink the tumor. Sometimes the tumors come back. Researchers think that treatment with drugs based on knowing the defective gene might give better results. Objective: \- To see if drugs selected based on the defective gene result in better tumor response. The drugs are Sunitinib and Everolimus. Eligibility: \- People age 18 and older with an advanced low- or intermediate-grade gastrointestinal or pancreatic neuroendocrine tumor. Design: * Participants will be screened with: * Medical history * Physical exam * Scans * Blood, urine, and lab tests * The study team will see if participants should have surgery. * If yes, participants will: * Sign a separate consent * Have computed tomography (CT) scan before and after surgery * Have as much of the tumor removed as possible. A small piece will be tested for mutation type. * If no, participants will have a small piece of tumor removed for the testing. * If the surgery might cure them, the participant will leave the study. The other participants will be assigned to take either Sunitinib or Everolimus. * Participants will take their drug by mouth once a day. They will keep a medicine diary. Some will keep track of their blood pressure at least weekly. * Screening tests may be repeated at study visits. Participants also may have their heart evaluated. * About 30 days after the last day of their study drug, participants will have a follow-up visit that repeats the screening tests. * Participants will be contacted every 3 months after this visit.
Detailed description public domain (ClinicalTrials.gov)
Background: * Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are a rare and heterogeneous group of neoplasms with unique tumor biology, natural history, and clinical management issues. * Most NETs are sporadic, but they can be part of familial cancer syndromes such as multiple endocrine neoplasia type 1 (MEN1), neurofibromatosis type 1 (NF1) or Von Hippel-Lindau (VHL) syndrome. * Well-differentiated, low or intermediate grade NETs have a heterogeneous natural history. * Surgery is the only curative treatment option in patients with localized early stage NETs. * The optimal management strategy for patients with advanced NETs is unknown. * The majority of NETs have somatic mutations in MEN1 and cyclin dependent kinase inhibitor 1B (CDKN1B), and genes involved in the phosphatidylinositol-3-kinase (PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway, and/or overexpression of growth factors and their receptors such as vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor (PDGF), and platelet-derived growth factor receptors (PDGFR) that can be targeted for therapy. * Survival in patients with NETs and somatic mutations is better than patients with wild type NETs. * Sunitinib (multi-tyrosine kinase inhibitor) and Everolimus (mTOR signaling pathway inhibitor) are currently approved for the treatment of progressive, unresectable, locally advanced or metastatic pancreatic NETs. * However, mutation targeted therapy with Sunitinib or Everolimus has not been studied in this patient population. * The present proposal aims to determine if mutation targeting therapy for patients with advanced low- or intermediate grade NETs is more effective than historically expected results. Objectives: -To determine the progression-free survival in patients with NETs of the gastrointestinal tract and pancreas treated with Sunitinib or Everolimus based on tumor genotyping. Eligibility: -Patients with: * progressive, histologically or cytologically diagnosed low or intermediate grade locally advanced or metastatic NETs. * Age greater than or equal to 18 years Design: * Phase II open labeled clinical trial. * Tumor biopsy for tumor genotyping will be performed if the patient does not have archival tissue available and does not have MEN1, VHL or NF1. * Patients with somatic or germline mutations in MEN1/PDGFR/KIT/FMS-like tyrosine kinase-3 will be treated with Sunitinib. (Arm 1) * Patients with somatic/germline mutations in NF1/PTEN/PI3K/AKT/mTOR/VHL will be treated with Everolimus. (Arm 2) * Patients with wildtype tumor will be treated with Sunitinib. (Arm 1) * Patients who have disease-progression on either Sunitinib or Everolimus will cross-over to the other drug. * Treatment will continue until disease progression, unacceptable toxicity, or consent withdrawal. * Up to 120 patients will be accrued to the study. It is anticipated that 20-30 patients per year may enroll into this trial; thus accrual may be completed in 4-5 years.
Intervention public domain (ClinicalTrials.gov)
Drug: Sunitinib. 37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
Intervention public domain (ClinicalTrials.gov)
Drug: Everolimus. 10 mg daily will continue until progression or unacceptable treatment-related toxicity
Arm public domain (ClinicalTrials.gov)
1/ Arm 1 Sunitinib (experimental): Sunitinib
Arm public domain (ClinicalTrials.gov)
2/ Arm 2 Everolimus (experimental): Everolimus
Primary outcome public domain (ClinicalTrials.gov)
Median Amount of Time Subject Survives Without Disease Progression After Treatment. Median amount of time subject survives without disease progression after treatment. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions. Time frame: Up to approximately 2 years.
Secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With an Overall Response. Time frame: Every 3 months until disease progression, up to 12 months.
Secondary outcome public domain (ClinicalTrials.gov)
Overall Survival. Time frame: Up to approximately 4 years.
Secondary outcome public domain (ClinicalTrials.gov)
Median Survival Time (MST). Time frame: Death, an average of 12 months follow up.
Secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Serious and Non-Serious Adverse Events. Time frame: Date treatment consent signed to date off study approximately 49 months and 9 days..
Eligibility public domain (ClinicalTrials.gov)
-INCLUSION CRITERIA: 1. Progressive, histologically or cytologically diagnosed low or intermediate grade, neuroendocrine tumors confirmed by the Laboratory of Pathology, National Cancer Institute (NCI). Disease progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progression of disease or any new lesions seen on 68-Gallium DOTATATE within the 18 months prior to enrolment. 2. Age greater than or equal 18 years, because the incidence and prevalence of metastatic pancreatic and gastrointestinal neuroendocrine tumors in the pediatric patient population is exceedingly rare (children are excluded from this study, but will be eligible for future pediatric trials). 3. Patients must have measurable disease according to RECIST criteria on anatomic imaging studies (computed tomography (CT) scan or magnetic resonance imaging (MRI)). 4. Willingness to undergo tumor biopsy if the patient does not have a known familial cancer syndrome (multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau (VHL) and neurofibromatosis type 1 (NF1)). Archival tissue available. 5. Eastern Cooperative Oncology Group (ECOG) performance status \<2. 6. Patients must have normal organ and bone marrow function as defined below: * hemoglobin greater than or equal 9 g/dL \* * leukocytes greater than or equal 3,000/mcL \* * absolute neutrophil count greater than or equal 1,500/mcL \* * platelets greater than or equal institutional lower limit of normal * total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) less than or equal 2.5 times institutional upper limit of normal (less than or equal 5 times upper limit of normal (ULN) in patients with liver metastases) \- creatinine within normal institutional limits OR * creatinine clearance greater than or equal 60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal. * International Normalized Ratio (INR) less than or equal 2; * If a patient's bone marrow function falls below the indicated values and it is not thought to be related to prior treatments a hematology consult will be ordered. If Hematology deems the patients safe to proceed with treatment they will be allowed to enroll on study. In such cases, the patients absolute neutrophil count must be greater than 1,000/mcl, hemoglobin must be greater than 7.5 g/dL and …
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 16 participants (actual).
Why stopped public domain (ClinicalTrials.gov)
Study closed due to poor accrual.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Median Amount of Time Subject Survives Without Disease Progression After Treatment [Up to approximately 2 years]. Median, months (Full Range). Sunitinib First, Everolimus Second (n=14): 7 (3 to 15); Everolimus First, Sunitinib Second (n=2): 18 (0 to 18).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With an Overall Response [Every 3 months until disease progression, up to 12 months]. Count Of Participants, Participants. Sunitinib First, Everolimus Second (n=14): 1; Everolimus First, Sunitinib Second (n=2): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival [Up to approximately 4 years]. Median, Months (Full Range). Sunitinib First, Everolimus Second (n=14): 25.5 (6 to 39); Everolimus First, Sunitinib Second (n=2): 10.7 (0.427397 to 21).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Median Survival Time (MST) [Death, an average of 12 months follow up]. Median, Months (Full Range). Sunitinib First, Everolimus Second (n=14): 9.5 (0.4927 to 33); Everolimus First, Sunitinib Second (n=2): 5.5 (0 to 11).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Serious and Non-Serious Adverse Events [Date treatment consent signed to date off study approximately 49 months and 9 days.]. Count Of Participants, Participants. Sunitinib (n=15): 15; Everolimus (n=11): 11.
Papers 3
- Registry-listed results paperONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPA… DOI 10.4158/ep-2018-0603↗
- Builds on itNeuroendocrine Tumor of the Pancreas as a Manifestation of Cowden Syndrome: A Case Report. DOI 10.1210/jc.2015-3684↗
- BackgroundMutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroe… DOI 10.1136/bmjopen-2015-008248↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.